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COFACTOR OF BRCA1 AS A MODULATOR OF HEPATOCELLULAR
CARCINOMA GROWTH AND MIGRATION

ABSTRACT

Cofactor of BRCA1 (COBRA1) is one of the four subunits that make up the Negative
Elongation Factor Complex (NELF) which is involved in the stalling of RNA polymerase II
early during transcription elongation. As such, COBRA1 is able to regulate a substantial
number of genes involved in a number of pathways, including cell cycle control,
metabolism, cell proliferation and DNA repair. In the field of cancer, the role of COBRA1 is
not yet fully understood. The aim of our study was to investigate the functional role of
COBRA1 in the tumorigenesis of hepatocellular carcinoma (HCC). We investigated the
gene expression pattern of COBRA1 in HCC tumors using the publicly available Oncomine
Cancer Microarray Database. Results from three different microarray datasets reveal the
frequent overexpression of COBRA1 in HCC tumors versus their normal counterparts. To
elucidate the biological significance for this overexpression in HCC, RNA interference was
used to silence the expression of COBRA1 in the well differentiated HCC cell line, HepG2.
The silencing efficiency was confirmed by both reverse transcription-polymerase chain
reaction (RT-PCR) and Western blot analysis. Interestingly, knockdown of COBRA1
resulted in a significant decrease in cell proliferation, accompanied by a concomitant
decrease in the expression of the proliferation marker, Ki-67. A scratch wound healing
assay revealed a significant decrease in the migratory potential of the HepG2 cell line in
culture upon COBRA1 knockdown. In addition, silencing of COBRA1 was associated with
a significant decrease in the expression of survivin, suggesting that survivin might be one
of the mechanisms by which COBRA1 mediates its role in the tumorigenicity of HCC.
Collectively, data findings presented here highlight an oncogenic role for COBRA1 in
hepatocellular carcinoma. To the best of our knowledge, our study provides evidence for
the first time to support a positive role for COBRA1 in the growth and migration of HCC.
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CHAPTER 1. LITERATURE REVIEW

1.1 Hepatocellular Carcinoma
1.1.1 Statistics and Epidemiology
Liver cancer is the second most frequent cause of cancer-related deaths worldwide,
responsible for more than 0.5 million deaths globally per year and accounting for 0.5–1
million newly diagnosed cases each year (Ferlay et al., 2013; Jemal et al., 2011).
Hepatocellular carcinoma (HCC) accounts for 70- 85% of all liver cancer cases; thereby
representing by far the most common type of liver cancer (Jemal et al., 2011). It is a male
predominant cancer, affecting males 3 to 4 times more frequently than females (Guy &
Peters, 2013). The incidence of the disease increases with age, occurring rarely before the
age of 40 years and reaching its peak at about 70 years of age (El-Serag, 2011).

HCC is considered one of the most aggressive cancers worldwide affecting primarily
developing countries, which harbor more than 80% of all presented cases worldwide (ElSerag, 2011). According to GLOBOCAN, Egypt has one of the highest incidences of liver
cancer, ranking first in the most common cancer affecting men while second in those
affecting women (Ferlay et al., 2013). Incidence rates in Egypt were reported to have nearly
doubled from 4.0% in 1993 to 7.2% in 2003 (el-Zayadi et al., 2005). This is primarily
attributed to the high hepatitis C virus (HCV) prevalence rates in the country, which is by
far the highest worldwide reaching up to 20% and representing one of the major risk factors
for the development of HCC (Lehman et al., 2008; Omar, Abou-Alfa, Khairy & Omar, 2013).

1.1.2 Etiology

The majority of HCC cases (80 -90%) develop from cirrhotic livers; rarely does a HCC case
develop from a patient that has no cirrhotic liver (El-Serag, 2011). Factors predisposing to
liver cirrhosis are therefore considered risk factors for the development of HCC and include
chronic hepatitis B virus (HBV) infection, chronic HCV infection, chronic alcohol
consumption and dietary aflatoxin consumption (Montalto et al., 2002). Other risk factors
such as diabetes, obesity, metabolic syndrome, hemochromatosis and nonalcoholic fatty
liver disease have been proposed to play a role in the development of HCC, however, to a
much lesser extent (Farazi & DePinho, 2006).

Chronic HCV infection has currently the largest share in the incidence of HCC, accounting
for about 40-50% of cases (Omar et al., 2013). Prior to the introduction of the HBV vaccine,
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HBV infection was the risk factor that had the largest contribution towards the development
of HCC in Egypt. The influence of HBV on the etiology of HCC has however declined over
the past 2 decades, owing to the introduction of routine mandatory HBV vaccinations and
to the large increase in the prevalence of HCV (Lehman et al., 2008; Omar et al., 2013).
Despite this decline, chronic HBV infection still remains an important risk factor for HCC as
the vaccination program, although estimated to have a childhood coverage of 95-100%,
was not initiated until the 1980s and therefore most adults over the age of 30 years are not
vaccinated (Lehman et al., 2008).

Another major contributor to the development of HCC worldwide is chronic aflatoxin
consumption. Aflatoxins are carcinogenic fungal metabolites, produced mainly by fungal
species Aspergillus flavus and parasiticum and contaminates many food products such as
peanuts, maize and cottonseed. The presence of aflatoxins is more common in countries
with hot and humid climates, which support the growth of the fungi (Waly Raphael, Yangde,
& Yuxiang, 2012). Several lines of evidence are recently suggesting that aflatoxin is a
growing risk factor for HCC in Egypt (Omar et al., 2013).

1.1.3 Surveillance and Diagnosis

Early stage HCC is asymptomatic and therefore difficult to clinically diagnose. As a result,
most HCC patients are usually diagnosed at an advanced stage, when treatment options
are limited. Surveillance is thus recommended for patients at high risk of HCC in order to
allow for the early detection of HCC (El-Serag, 2011; Forner, Llovet, & Bruix, 2012).

According to both the American Association for the Study of Liver Diseases (AASLD) and
the ESMO Clinical Practice Guidelines, surveillance for HCC in liver cirrhosis patients
should be done every 6 months using abdominal ultrasound (El-Serag, 2011; Verslype,
Rosmorduc, & Rougier, 2012). Although alpha-fetoprotein (AFP) is the most widely used
serological marker for the diagnosis and follow-up of HCC, it suffers from a limited
sensitivity of 60-80% and thus guidelines do not recommend its use for surveillance (Forner
et al., 2012).

1.1.4 Prognosis and Available Treatments
Despite the different treatment regimens available, prognosis of HCC still remains very
poor with an overall 5-year survival rate less than 5% (X. Huang, Zheng, & Yuan, 2013).
More than 0.5 million lives are lost worldwide every year to hepatocellular carcinoma
(Jemal et al., 2011). This is attributed to the fact that potential curative therapies, which
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includes either surgical resection or liver transplantation, are ideal for only a small subset
of early HCC cases. Unfortunately, more than 50% of all HCCs are diagnosed at an
advanced stage or at metastasis, making them ineligible to either treatment (X. Huang et
al., 2013). For patients with early HCC and well-compensated cirrhosis, the superiority of
one treatment over the other remains controversial and management will depend from one
patient to another (Kim & Hemming, 2009)
Liver transplantation (LT), theoretically, is considered an ideal treatment as it does not only
remove the tumor, but cures the underlying disease as well (Forner et al., 2012). It has
been associated with better overall and disease-free survival in well-selected patients
(Bismuth et al., 1993). When used for small HCCs, survival rates have been reported
similar to transplantations performed for non-HCC indications (Hemming et al., 2001). The
criteria used to define ideal candidates for LT are collectively referred to as the Milan
criteria (Forner et al., 2012; Morise et al., 2014). Within the Milan criteria, overall and
disease-free survival at 4 years have been reported to be 92% and 85%, respectively while
recurrence rates have been demonstrated to be as low as 4-10% (Kim & Hemming, 2009).
However, LT suffers from a major limitation, besides from being an option available only to
a small subset of patients. As a result of a shortage in donor organs, the transplant list is
usually associated with long waiting times that patients do not have. With the inevitable
progression of the HCC tumor, patients do eventually drop out from the list without
receiving a transplant as they become with time ineligible for the procedure (Fortune,
Umman, Gilliland, & Emre, 2013).

Surgical resection suffers from a major drawback. Even with the thorough criteria put in the
selection of surgical candidates, tumor recurrence is very common reaching up to 50-80%
of the patients at 5 years following resection, with the majority occurring in the first 2 years
(El-Serag, 2011; Kim & Hemming, 2009). It is believed that recurrence may either represent
a dissemination from the primary tumor or a ‘de novo’ tumor in the remnant liver.
Controversy however exists about the contribution of each. Dissemination from the primary
tumor is considered the result of either microscopic tumor foci that have been missed by
common imaging techniques and thus have not been taken into consideration, or
cancerous cells that have spread during the surgical procedure (X. Huang et al., 2013).
Despite the discussed drawbacks, liver resection remains an attractive option due to its
availability and the fact that it is curative in 45% of eligible patients (Kim & Hemming, 2009).
Besides surgical options, other treatments do exist for the management of HCC and
include ablative (radiofrequency ablation, transarterial chemoembolization), and medical
treatments (chemotherapy), however, they are usually performed either as palliative
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treatment for patients who are ineligible for surgical treatment or as ‘bridging’ therapy for
patients awaiting liver transplantation (Jelic & Sotiropoulos, 2010)

1.1.5 Molecular Classification of HCC

The inadequate availability of molecular markers has led to significant reliability on
morphological features for the diagnosis of HCC. This makes early stages of HCC difficult
to diagnose. This is due to the fact that clinicopathological features of early stages deviate
only slightly from chronic liver disease (CLD). Important diagnostic features typically
associated with more advanced forms of the disease such as radiologic findings, increased
vascularity, elevated serological markers and histological atypia are not typically present
in the early stages. Consequently, over 50% of HCCs are detected at an advanced stage
and thus are limited to more palliative forms of treatment (X. Huang et al., 2013; Jelic &
Sotiropoulos, 2010).

Research currently aims to identify expression profiles and signatures associated with
early HCC (Mas et al., 2009; Sakamoto, Effendi, & Masugi, 2010). From ~12,600 genes
analyzed in a gene-expression profiling study performed on nodule-in-nodule type HCC,
heat shock protein 70 (hsp70) was reported to be significantly upregulated in the early
component of the cancer when compared to either its progressed counterpart or
noncancerous liver (Chuma et al., 2003). The fact that hsp70 expression was undetectable
in other benign nodular lesions, hepatocellular adenoma and focal nodular hyperplasia,
indicated the potential of such a marker in differentiating early HCC from other benign liver
lesions (Sakamoto, 2009). Comparable approaches have suggested other potential
markers of early HCC as well such as, cyclase-associated protein2 (CAP2) (Shibata et al.,
2006), glypican-3 (GPC3) (Hippo et al., 2004) and glutamine synthetase (GS) (Osada et
al., 1999). Di Tommaso et al. (2007) demonstrated that a combination of the 3 markers,
HSP70, GPC3 and GS can promote the accuracy of diagnosing early HCC, indicating thus
the applicability of using a panel of markers instead of just one to allow for increased
accuracy in diagnosis.

Similar attempts were carried out to subclassify HCC. Studies successfully identified gene
expression profiles that can distinguish HBV- from HCV-associated HCC, early from late
intrahepatic recurrence of HCC, and HCCs with different prognoses (Farazi & DePinho,
2006; Mas et al., 2009; Roessler et al., 2010; Wurmbach et al., 2007).

Proper HCC management remains largely hindered by the lack of molecular biomarkers
for the early diagnosis, prognosis & therapy monitoring of HCC. The hope of finding truly
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sensitive and specific molecular markers to subclassify HCC and hence, to support patient
management is still in its infancy and requires further extensive research.

1.1.6 Molecular Biology of HCC Progression

The exact mechanisms lying behind the development and progression of HCC remain very
much a mystery. Several signaling pathways are known to be deregulated in HCC such as
the IGF, Wnt/β-catenin, TGF-β, Ras/MAPK, VEGF, EGFR, HGF/MET and P13/PTEN/AKT
pathways (Cornellà, Alsinet, & Villanueva, 2011; Waly Raphael et al., 2012). In addition to
the disrupted signaling pathways, HCC is associated with a large number of activated
oncogenes and suppressed tumor-suppressor genes such as TP53, ErbB receptor family
members, E-cadherin and cyclooxygenase 2. Genomic instability has also been described
in HCC in the form of defects in chromosomal segregation (Farazi & DePinho, 2006).

Despite significant progress in the understanding of the genetic and epigenetic changes
associated with HCC, we are still a long way from a clear understanding of the molecular
mechanisms that govern the multi-step progression or evolution of the disease. This is
largely due to the heterogeneity and underlying complexity of the disease. Therefore,
research in HCC is currently directed towards the characterization of these molecular
mechanisms. A more comprehensive understanding of this progression will in effect allow
the discovery of novel treatment strategies (Cornellà et al., 2011; Wong & Ng, 2008).

Up until recently no systemic chemotherapy was available for HCC. However, in 2007, a
recently discovered Raf kinase inhibitor (Sorafenib, NEXAVAR®) was approved by the US
Food and Drug Administration (FDA) for use in HCC. By targeting the RAF/MEK/ERK
pathway, Sorafenib shows antiproliferative, antiangiogenic, and proapoptotic activity (S.
Wilhelm et al., 2006). In a phase III randomized controlled trial (SHARP), it was able to
increase overall survival in patients with advanced HCC by about 3 months (Llovet et al.,
2008). Shortly after its discovery, Sorafenib was shown capable of inhibiting a number of
other receptor tyrosine kinases as well involved in tumor progression. Thus, why it is
currently referred to as a multi-kinase inhibitor (S. M. Wilhelm et al., 2008).

As discussed earlier, characterization of the unique genetic changes associated with HCC
will not only allow a more comprehensive understanding of the genetic basis of the disease
but will also allow the discovery of more promising targets for therapy. In this study, our
interest lies in one of the genes recently implicated as a potential player in the development
and progression of several cancers, known as COBRA1.
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1.2 Cofactor of BRCA1

Cofactor of BRCA1 (COBRA1) was originally isolated from a human ovary cDNA library. It
encodes a 580-amino acid leucine-enriched protein with 3 repeats of the LXXLL motif (Lleucine, X-any amino acid). This motif, commonly present in transcription coactivators, is
responsible for mediating ligand-dependent interactions with nuclear receptors (NRs) (Ye
et al., 2001). The importance of COBRA1 was later established through in vivo studies,
where a general knockout of the murine Cobra1 gene was shown to be lethal in the embryo.
In addition, no COBRA1-/- embryos appeared to develop beyond embryonic day 5,
indicating an important role for COBRA1 in early embryogenesis (Amleh et al., 2009).

COBRA1 was initially identified as a novel BRCA1 interacting protein through a yeast twohybrid screen (Ye et al., 2001). It was not until later that Narita et al. (2003) identified
COBRA1 as the same protein as NELF-B, one of the 4 subunits that make up the human
negative elongation factor (NELF) complex. NELF is a well-characterized complex involved
in the stalling of RNAPII during transcription elongation and hence, responsible for the
regulation of a significant number of genes involved in cell cycle control, proliferation,
metabolism as well as cellular responses to stimuli and stress (Sun & Li, 2010).
In eukaryotes, COBRA1’s role in the regulation of gene expression is not limited by any
means to its interaction with BRCA1 and NELF. With no DNA binding domain, COBRA1’s
ability to regulate genes occurs via its interaction with other site-specific transcription
factors. In fact, it was shown to act as a cofactor for another complex known as Activator
Protein-1 (AP-1), to regulate AP-1’s transcriptional activity of downstream targets (Zhong
et al., 2004). Given the major role the AP-1 signaling pathway plays in determining cellular
fate, it is postulated that COBRA1 will have a similar contribution to those cellular decisions.

In 2004, Aiyar et al. demonstrated a novel role for COBRA1 as a transcriptional corepressor
in the repression of hormone-responsive transcription. It was shown to directly bind to
estrogen receptor-alpha (ERα) and repress ERα-mediated gene transcription (Aiyar et al.,
2004). Given the positive role ERα-mediated signaling has on the development of breast
cancer (Foster, Henley, Ahamed, & Wimalasena, 2001; Persson, 2000), COBRA1’s
physiological role in suppressing the estrogen-dependent growth of breast cancer cells
was illustrated and established (Aiyar et al., 2004). In agreement, lack of COBRA1 in breast
cancer was later demonstrated a poor predictor of prognosis (Sun et al., 2008).
In addition to ERα, COBRA1 was also reported to bind with various degrees of affinity to
other nuclear receptors such as the progesterone receptor B (PRB) and the glucocorticoid
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receptor (GR). In particular, COBRA1 was demonstrated to strongly bind to the androgen
receptor (AR) & repress AR-mediated transcription (Sun, Blair, Aiyar, & Li, 2007). Similar
to the ERα-signaling pathway, AR-mediated signaling is also well established in mediating
the development and/or progression of different malignancies such as prostate cancer and
HCC (Lonergan & Tindall, 2011; Ma, Lai, Yeh, Cai, & Chang, 2014). However, the role that
COBRA1 or NELF-B plays in these different malignancies has not been yet studied and
remains unknown.
Even though COBRA1 has been extensively studied over the years, in the field of cancer,
the role of COBRA1 is not yet fully understood. In this study, our interest lies in unraveling
the role of COBRA1 in HCC. A summary of current knowledge of COBRA1 however will
be first reviewed below.

1.2.1 Breast Cancer Type 1 Susceptibility Protein (BRCA1)

BRCA1 is the first breast and ovarian cancer susceptibility gene to be identified. Germ line
mutations in BRCA1 predispose patients to familial breast and ovarian cancers and are
responsible for 50% of all familial early onset breast cancers, which account for ~2-5% of
all breast cancers (Couch & Weber, 1996; Ye et al., 2001). It represents one of the most
recognized tumor suppressors and is currently widely used to diagnose the likelihood of
patients to develop breast and ovarian cancer.
Being a predominantly nuclear protein, BRCA1 is normally involved in multiple nuclear
functions, including the regulation of transcription, recombination, checkpoint control and
DNA repair. These functions are mediated via its ability to induce large-scale chromatin
unfolding (Ye et al., 2001). In an attempt to identify cofactors recruited by BRCA1 to induce
chromatin unfolding, Ye et al. (2001) employed a yeast two-hybrid screen and discovered
a novel protein that was named cofactor of BRCA1 (COBRA1). Surprisingly, COBRA1 was
reported sufficient for the induction of large-scale chromatin decondensation in the
absence of BRCA1 (Ye et al., 2001).

In a gene expression profiling study performed in breast cancer, a significant overlap was
uncovered in the genes that are regulated by COBRA1 or BRCA1. Both have been shown
to share common downstream target genes, many of which have been implicated in breast
cancer progression (Aiyar, Cho, Lee, & Li, 2007). In agreement, similar to BRCA1’s
recognized role as a tumor suppressor in breast cancer, several lines of evidence have
been reported that highlight a role for COBRA1 as a tumor suppressor in breast cancer as
well (Sun et al., 2008). However, this will be discussed later.
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1.2.2 Negative Elongation Factor Complex (NELF)

Shortly after its initial discovery in 2001, COBRA1 was identified by Narita et al. (2003) as
the same protein as NELF-B, one of the 4 subunits that make up the NELF complex. NELF
is a complex that is activated with the assembly of its 4 subunits; NELF-A, NELF-B (or
COBRA1), NELF-C/D and NELF-E. Upon assembly and activation, the complex is
recruited together with DRB sensitivity-inducing factor (DSIF) to induce the stalling of RNA
polymerase II (RNAPII) early during transcription elongation. It is believed that NELF
recruitment occurs immediately after transcription initiation, stalling the elongation of the
RNA transcript in a process referred to as promoter proximal pausing. This is characterized
by the association of NELF with a paused Pol II complex 30–50 bps downstream of the
transcription start site (Yamaguchi et al., 1999).

NELF is a 4-subunit complex; NELF-A (66 kDa), NELF-B (COBRA1; 62 kDa), NELF-C (60
kDa) or NELF-D (59 kDa) and NELF-E (46 kDa). The NELF-C and NELF-D subunits
represent translation variants from a common mRNA through the alternative use of
translation initiation codons. However, either NELF-C or NELF-D will be present in a NELF
complex at any one point. NELF-C/D together with COBRA1 (NELF-B) form the core of the
NELF complex, bridging NELF-A and NELF-E. The NELF-A subunit contains the RNAPII
binding domain, through which the NELF complex is able to bind to RNAPII. NELF-E is the
smallest subunit and contains a conserved RNA binding domain, through which the NELF
complex is able to bind to nascent RNA transcripts (Narita et al., 2003).

It is important to mention that although NELF-A and NELF-E are the binding domains by
which the NELF complex will bind to RNAPII and RNA, respectively, all of the four subunits
including COBRA1 (NELF-B) and NELF-C/D are necessary for the assembly and function
of the complex (Narita et al., 2003). In fact this explains the well-established interdependent
nature of the NELF subunits, whereby knockdown of any NELF subunit results in the
simultaneous co-depletion of the remaining subunits (Narita et al., 2007; Sun & Li, 2010;
Sun et al., 2008).

There are three major steps to transcription: initiation, elongation and termination, each of
which is now known to be tightly controlled. Originally, the transcriptional regulation of
eukaryotic genes was believed to occur almost exclusively at the initiation phase of
transcription. Hence, it had been the focus of much research and is why it is considered to
be the most understood phase of transcription. However, recent findings have revealed
that the elongation step of transcription is also a very highly regulated step and can actually
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be rate-limiting in the regulation of the expression of many genes in eukaryotic cells (J.Sims
III, Belotserkovskaya, & Reinberg, 2004).

The elongation step is regulated both during the early steps of elongation as well as during
the phase of productive elongation. During early elongation, just before the RNAPII
transitions to productive elongation, RNAPII can pause at the promoter proximal region,
30–50 base pairs (bps) downstream of the transcription start site in a process referred to
as promoter proximal pausing. Contrary to transcriptional termination or arrest, promoter
proximal pausing is reversible and represents one of the important mechanisms by which
transcription can be regulated at the elongation phase (Adelman & Lis, 2012; J.Sims III et
al., 2004; Jonkers & Lis, 2015).

Even though, the process of RNAPII stalling was well established, it was reported only at
the promoters of very few genes such as Hsp70 (Wu et al., 2003), estrogen-responsive
genes in breast cancer (Aiyar et al., 2004) and mammalian proto-oncogene junB (Aida et
al., 2006), leading many to view it as a rare phenomenon. It was not until later that genomewide studies in Drosophila demonstrated the association of RNAPII with the promoters of
thousands of genes with either low levels of transcription or none at all, in an indication
that the process of RNAPII stalling is more widespread than originally anticipated (Muse et
al., 2007; Zeitlinger, Stark, Kellis, & Hong, 2007). Now, the regulation of RNAPII pausing
during transcription elongation is believed to be cornerstone in the repression of a large
number of genes in a variety of biological systems (Gilchrist et al., 2008).

Surprisingly, stalled RNAPII was found associated in the promoter regions of ~50% of the
most highly expressed genes in Drosophila, demonstrating the capability of promoter
proximal pausing of enhancing gene expression rather than only repressing it (Gilchrist et
al., 2008; Lee et al., 2008). Even though this was the first time the NELF-mediated RNAPII
stalling event was shown to have a positive effect on activating gene expression, a previous
microarray study reported the downregulation of a significant number of genes upon NELFdepletion (Narita et al., 2007). However, it was not until later that this phenomenon was
understood and linked directly to the NELF-mediated RNAPII stalling event. In fact, it is
now even believed that the stalling process of RNAPII might enhance gene expression by
maintaining a permissive chromatin architecture at the promoter-proximal region of those
genes (Gilchrist et al., 2008). This was again further demonstrated in yet another study
whereby short interfering RNA (siRNA)-mediated knockdown of NELF lead to the downregulation of the vast majority of NELF-regulated genes, most of which are involved in cell
cycle progression (Sun & Li, 2010). Taken together, this indicated the importance of NELF
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in maintaining the transcription of its target genes and challenged the prior view of RNAPII
stalling being a strictly transcriptional repressor.

1.2.3 Nuclear Receptors
Upon binding of estrogen to ERα, the receptor undergoes conformational changes and
becomes activated. An activated ERα will then bind to estrogen-responsive elements
present in the promoters of estrogen-responsive genes to enhance their transcription. ERα
represents one of the mechanisms by which estrogen is able to mediate its widespread
biological effects, under both physiological and pathological conditions (Aiyar et al., 2004).

Different mechanisms are normally in place in order to allow for such a process to be tightly
regulated and readily reversible. In 2004, Aiyar et al. demonstrated a novel role for
COBRA1 as a transcriptional corepressor in the repression of estrogen-responsive
transcription. In response to estrogen, COBRA1 is recruited along with the rest of the NELF
complex, to the promoters of a subset of estrogen-responsive genes where it acts to stall
RNAPII and repress ERα-mediated transcription. Given the positive role ERα-mediated
signaling has on the development of breast cancer (Foster et al., 2001; Persson, 2000), a
physiological role for COBRA1 as an inhibitor of estrogen-dependent growth of breast
cancer cells was established (Aiyar et al., 2004).
In addition to ERα, COBRA1 was also shown to bind with various degrees of affinity to
other NRs such as PRB and GR. In particular, COBRA1 was reported to bind strongly to
the AR and repress AR-mediated transcription. Of the NRs examined in the study (GR, PR
and AR), AR was shown to exhibit the strongest affinity for COBRA1 and thus, the most
susceptible to COBRA1-mediated repression (Sun et al., 2007). COBRA1’s interaction with
a number of nuclear receptors goes in agreement with its previously characterized protein
structure, which contains multiple copies of NR-binding “LXXLL” motifs (Ye et al., 2001).

1.2.4 AP-1 Complex

The biological roles of COBRA1 is yet to be fully elucidated. With no DNA binding domain
of its own, its ability to regulate genes is mediated via its interaction with different DNA
transcription factors, as seen with both BRCA1 and the NELF complex. COBRA1 was
shown to interact with yet another widely recognized transcription factor, known as AP-1
(Zhong et al., 2004). AP-1 is a complex that regulates the expression of a large number of
genes; genes involved in mediating cellular responses to stimuli, including growth factors,
cytokines, stress, bacterial and viral infections as well as oncogenic stimuli (Hess, Angel,

10

& Schorpp-Kistner, 2004). The AP-1 signaling pathway, while essential for cell survival,
extensive literature exists to support its role in inducing apoptosis. The role of AP-1 in
determining cellular fate (life or death) appears to largely depend on cellular context. Its
opposing nature on cell fate has interestingly triggered some to refer to it as a “nuclear
decision-maker” (Ameyar, Wisniewska, & Weitzman, 2003).

COBRA1 was shown to act as an AP-1 cofactor, where it was shown to physically bind to
AP-1 family members and inhibit AP-1 transcriptional activity of downstream targets. It has
been proposed that COBRA1 may utilize its ability to recruit the NELF complex in order to
attenuate AP-1 transcriptional activity; however, this has not been shown and renders
further investigation. Given COBRA1’s ability in affecting the AP-1 pathway, COBRA1 has
also been proposed to have an identical role in determining cell fate decisions, such as
proliferation, apoptosis and differentiation (Zhong et al., 2004).

1.3 COBRA1 in Cancer

The pathological role of NELF-B or COBRA1 in cancer is not yet fully understood and is of
current interest. To date, it has only been studied in breast and gastrointestinal cancer.
In breast cancer, several lines of evidence highlight COBRA1 as a tumor suppressor with
a major role in the tumorigenicity of the cancer. In a study by Sun et al. (2008), COBRA1
expression was demonstrated lower in breast cancer when compared to normal mammary
epithelium. In addition, the expression of COBRA1 mRNA was also found to be inversely
correlated with breast cancer progression, with significantly lower expression in patients
with distant metastasis and local recurrence (Sun et al., 2008).

COBRA1-regulated genes were found to enrich pathways involved in cell cycle control,
metabolism, cell proliferation and DNA repair. In addition, a significant number of these
identified genes had wide implications in cancer. The direction of COBRA1’s regulation of
these genes was found to support its role in suppressing breast cancer development (Aiyar,
Blair, Hopkinson, Bekiranov, & Li, 2007; Aiyar, Cho, et al., 2007). This goes in line with the
previously reported role of COBRA1 in the proliferation and tumorigenesis of breast cancer.
In that study, the authors demonstrated a significant reduction in the rate of proliferation of
T47D cells upon the ectopic expression of COBRA1 (Aiyar et al., 2004). Similarly, siRNA
knockdown of COBRA1 resulted in an increase in cellular proliferation as assessed by both
two- and three-dimensional tissue culture systems. Surprisingly however, the increase in
cellular proliferation was evident only when exogenous estrogen was added to the culture
media, indicating thus a physiological role for COBRA1 in repressing the estrogendependent growth of breast cancer cells (Aiyar et al., 2004). The absence of estrogen
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might explain why COBRA1 knockdown in a later study by Sun & Li (2010) was shown to
have no effect on the cell proliferation of T47D. In agreement, subsequent findings
associated the low expression of COBRA1 with metastasis and recurrence in breast cancer
(Sun et al., 2008).

In contrast to breast cancer, significant overexpression of COBRA1 was reported in 79%
of upper gastrointestinal cancers (UGCs), suggesting COBRA1 as a novel oncogene in

UGC. Interestingly, COBRA1 overexpression was found associated with an attenuated
expression of trefoil factor 1 (TFF1) (McChesney et al., 2006) – a well-established UGC
tumor suppressor (Im et al., 2012; Tanaka et al., 2013). TFF1 is a member of the trefoil
factor family of secreted peptides that is normally expressed and secreted in the upper
gastrointestinal tract, with several protective and healing roles (Emami et al., 2004). While
COBRA1 knockdown led to an increase in TFF1 expression, overexpression of COBRA1
had an opposite effect, thus highlighting the physiologic role of COBRA1 as an inhibitor of
TFF1 expression in UGC (McChesney et al., 2006). This evidence further supported the
oncogenic role for COBRA1 in UGCs.

Even though COBRA1 has only been studied in breast and gastrointestinal cancer only,
findings seem to highlight a cancer type-dependent role for COBRA1. It is also important
to mention that COBRA1 was recently identified in a proteomics study in lung cancer as a
novel target of the oncogenic Ras/MAPK signaling pathway (Sudhir et al., 2011). This was
consistent with prior findings reported by Pohl et al. (2005), where COBRA1 was one of
the major downregulated genes upon the inactivation of the MAPK pathway in ovarian
cancer. Interestingly, this was accompanied by a profound decrease in the growth of the
ovarian cancer cells. Taken together, these data suggest an important role for COBRA1 in
cancer.

1.4 COBRA1 in Hepatocellular Carcinoma

In hepatocellular carcinoma, the role of COBRA1 remains unclear. To date, only one study
has analyzed the expression pattern of COBRA1 in HCC. This study explored the
differential expression of COBRA1 at both the RNA and protein level in HCC tumor
samples relative to noncancerous peri-tumor tissue from the same patient. Samples were
collected from Egyptian patients undergoing either surgical resection or transplantation
from different hospitals based in Cairo and an upregulated expression pattern was reported
implicating COBRA1 as an oncogene in HCC (Kamel, 2012). However, the biological role
that COBRA1 plays in the progression of HCC still remains unclear.
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HYPOTHESIS AND SPECIFIC OBJECTIVES

As a functional component of major transcriptional complexes and by acting as a cofactor
for several nuclear receptors, COBRA1 can regulate a substantial number of genes (Aiyar,
Blair, et al., 2007; Aiyar, Cho, et al., 2007). Based on previous preliminary data from our
lab implicating COBRA1 as a potential oncogene in HCC (Kamel, 2012), a deregulation in
the expression pattern of COBRA1 will imply aberrant expression of all its regulated genes.
Hence, our hypothesis for a role for COBRA1 in the pathogenesis of HCC. To address this
hypothesis, our study had three main objectives.
1. To expand on the lab’s prior findings and further explore on a larger scale the
expression pattern of COBRA1 in HCC expression array data available online.

2. To optimize and establish a siRNA-mediated COBRA1 knockdown in the well
differentiated HCC cell line, HepG2. The HepG2 cell line is a non-tumorigenic cell line
derived from a 15-year old Caucasian, American male with early stage HCC. The cells
have a characteristic cobblestone-like, epithelial appearance with no detectable HBV
surface antigens (Costantini, Di Bernardo, Cammarota, Castello, & Colonna, 2013).
3. To analyze the effect of COBRA1 silencing on cellular proliferation and migration.
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CHAPTER 2. MATERIALS AND METHODS

2.1. Cell lines and Culture
The well-differentiated human hepatocellular carcinoma cell line, HepG2, was a generous
gift from Dr. Mehmet Ozturk from the Department of Molecular Biology and Genetics,
Bilkent University, Turkey. Cells in the logarithmic phase of growth from passage numbers
6-20 were used in all experiments described below. They were routinely cultured in
complete media composed of RPMI 1640 (Invitrogen, USA) supplemented with 10% fetal
bovine serum (FBS) (Invitrogen, USA), 100 units/ml penicillin and 100 mg/ml streptomycin
(Invitrogen, USA). Cells were cultured in a humidified incubator at 37°C and 5% CO2 and
propagated at 70-80% confluence according to the American Type Culture Collection
protocol. Cells were observed using an inverted microscope (Olympus IX70, USA).

2.2. Viable Cell Count
The viable cell count was performed using the trypan blue exclusion method. The cell
suspension was mixed well by repeated pipetting to disperse any cell clumps. In a 1.5 ml
Eppendorf tube, a fifty μl aliquot of this cell suspension was mixed with 50 μl 0.4% trypan
blue in phosphate-buffered saline (PBS). Ten microliters (μls) from this suspension was
then loaded into each chamber of a hemocytometer (Hausser Scientific, USA). The number
of cells in each of the four outer squares in the two chambers were counted. To calculate
the number of cells per ml, the following equation was used:
Number of cells /ml = Total no. of cells / total no. of squares x dilution factor x 10,000.

2.3. RNA Interference
To achieve knockdown of COBRA1 (NCBI Genebank: NM_015456), a pool of 4 different
siRNAs targeting different regions of the COBRA1 mRNA (siGENOME SMARTPool; M015839-00) was used, which was purchased from Dharmacon. Target sequences and
exons of the COBRA1 siRNAs are shown in Table 1. Positive Control GAPDH siRNA
(SI02653266) and AllStars Negative Control siRNA (SI03650318) were purchased from
Qiagen. All siRNAs were resuspended in RNase-free water to a final concentration of 20
μM, according to the manufacturer’s instruction. Positive Control GAPDH siRNA was used
to ensure the efficiency of the transfection procedure in achieving siRNA delivery to the
cells. AllStars Negative Control siRNA is a validated and tested siRNA with no homology
to any known mammalian gene (“AllStars Negative Control siRNA - QIAGEN - AllStars
Negative Control siRNA,” n.d.), that was used to control for any changes induced by the
siRNA transfection procedure itself.
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2.4 siRNA Transfection
Reverse transfection of COBRA1 siRNA into HepG2 cells was carried out in 6-well plates
using Lipofectamine RNAiMAX (Life Technologies). An RNase-free environment was
maintained at all times. As controls, cells were either left untreated (blank) or treated with
Lipofectamine only (mock). The optimized transfection conditions mentioned below were
maintained in all experiments. Approximately 2.5 x 105 cells were reverse transfected with
25 nM of siRNA using 5 μl of Lipofectamine RNAiMAX according to the manufacturer’s
protocol in a final volume of 2 ml. In a 1.5 ml Eppendorf tube, 2.5 μl of the siRNA (20 μM)
was mixed with 500 μl of serum-free DMEM. After 5 minutes (mins) incubation at room
temperature (RT), 5 μl of Lipofectamine was added and then left for another 10-20 mins to
allow for complexation. The siRNA-Lipofectamine mix was then transferred to one of the
wells of a 6-well plate, after which 2.5 x 105 cells were added in 1.5 ml complete RPMI
media without antibiotics. Growth media was replenished 24 h after transfection. Cells were
cultured for 72 hours (hrs) after which they were harvested for RNA and protein analysis.
Knockdown efficiency was analyzed using Western blot analysis.

Table 1. Target sequences and the corresponding exon locations of COBRA1 siRNAs
(NCBI Genebank: NM_015456) used in the study.
siRNA Target Sequence (5’-3’)

Target Exon

1

CCGAAAGCUUCACUAAGUU

9 & 10

2

GCGACUUGGCCUUUGGCGA

11

3

GAGCCUGGGACAUGAUCGA

8

4

CGUCUAAGCUGGAGGCGUU

12

siRNA Identifier
siGENOME
SMARTPool
(M-015839-00)

2.5. RNA Extraction
Total RNA was extracted using Trizol reagent (Invitrogen, USA) according to the
manufacturer's protocol. An RNase-free environment was maintained at all times.
Extracted RNA was dissolved in diethylpyrocarbonate-treated (DEPC) water. The quantity
and quality of the RNA were verified by measuring the absorbance at both 260 and 280
nm using a UV spectrophotometer (Shimadzu, Japan).

2.6. Primer Design
All used forward and reverse primers are located on two different exons. The sequences
of these primers as well as their amplicon size and PCR conditions are listed in Table 2.
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Table 2. Semi-quantitative RT-PCR primer sequences, amplicon sizes, annealing
temperatures and number of cycles (F: forward primer, R: reverse primer, bp: base pair)
Gene
Name

Primer Sequence (5’-3’)

Amplicon
size (bp)

PCR
conditions

B-ACTIN

F: GCAAAGACCTGTACGCCAAC
R: GAGACCAAAAGCCTTCATACATCTC

777

58°C
27 cycles

COBRA1

F: ACATCACCAAGCAGAGGAA
R: GATCCAGCTGTTCCAGCTTC

366

59.5°C
32 cycles

Survivin

F: TTGAATCGCGGGACCCGTTGG
R: CAGAGGCCTCAATCCATGGCA

Isoform 1: 477
Isoform 2: 359
Isoform 3: 546

61˚C
27 cycles

NELF-A

F: GTCGGCAGTGAAGCTCAAGT
R: TTCACACTCACCCACCTTTTCT

250

60˚C
35 cycles

NELF-C/D

F: GAAGAAGGAGAGACCCCAGC
R: GTGCCCAAGGCTAGTGTGAT

443

56˚C
28 cycles

F: TGGTGAAGTCAGGAGCCATCAG
R: CGCCGTTCAGGGAATGAATC

565

63˚C
28 cycles

F: CTTTGGGTGCGACTTGACG
R: GTCGACCCCGCTCCTTTT

199

60˚C
28 cycles

NELF-E
Ki-67

2.7. Reverse Transcription Polymerase Chain Reaction (RT-PCR)
Analysis of differential gene expression was performed using semi-quantitative RT-PCR.
Total RNA (1 μg) was reverse transcribed using random primers in a final volume of 20 μl,
using a RevertAid First Strand cDNA synthesis Kit (Thermo Scientific, USA) according to
the manufacturer’s protocol.
The PCR amplification was performed in a final volume of 25 μl, consisting of 1 μl cDNA
template, 2.5 μl 10X DreamTaq Green Buffer (includes 20 mM MgCl2) (Thermo Scientific),
0.5 μl dNTP mix (10 mM each) (Thermo Scientific), 0.25 μl DreamTaq DNA Polymerase
(Thermo Scientific) and 0.75 μl of each primer (forward and reverse). B-ACTIN was used
as the internal control. PCR conditions were the same for all except for annealing
temperatures and cycle numbers, which are mentioned in Table 2: 95°C for 5 mins,
followed by cycles of (95°C for 30 secs, annealing temp for 30 secs and 72°C for 45 secs),
before a final extension at 72°C for 7 mins. The amplified PCR products were run on 1.52% agarose gel according to the size of the PCR amplicon and then visualized using Gel
Doc EZ System (Bio-Rad, USA).

2.8. Immunoblotting
Unless stated otherwise, all steps were performed at 4°C. Cells were rinsed with ice cold
PBS and lysed by repeating pipetting in ice-cold Laemmli Lysis Buffer (50mM Tris pH6.8,
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2% sodium dodecyl sulfate (SDS), and 10% glycerol), supplemented with 1X Halt Protease
Inhibitor Cocktail (ThermoScientific, USA). Samples were incubated at 4°C for 60 min with
shaking followed by centrifugation at 12,000 rpm at 4°C for 20 minutes. The proteincontaining supernatant was then collected and quantified using BCA Protein Assay Kit
(Pierce Biotechnology, USA) according to the manufacturer’s protocol.
Equal amounts of whole cell lysates (20-50 μg) were mixed with 6X SDS-Laemmli loading
dye (60% Glycerol, 360 mM Tris-HCl pH 6.8, 12% SDS, 0.06% bromophenol blue, 30%
beta-mercaptoethanol) in a final volume of 24 μl. Samples were boiled at 99°C for 10 mins
before loading them onto a 12% SDS–polyacrylamide gel. The protein samples were then
run at 120V along with a pre-stained protein ladder until the tracking dye ran out. Resolved
proteins were transferred from the gel onto a nitrocellulose membrane (GE Healthcare)
using a wet transfer apparatus (120 V, 90 mins). The membrane was blocked for 1 hr using
5% non-fat dry milk in 1X PBST (0.01% Tween-20 in PBS), then incubated with a primary
antibody overnight at 4°C. After 3 washings in 1X PBST (5 mins each), the membrane was
incubated 1 hr at RT with an alkaline phosphatase conjugated secondary antibody (either
goat anti-rabbit IgG (KPL) or goat anti-mouse (KPL)) at 1:10,000 dilution in 5% non-fat dry
milk in 1X PBST. After 3 washes in 1X PBST (5 mins each) and two in 0.2 M Tris base (pH
9-9.5), the membrane was incubated with the chemiluminescent PhosphoGLO Substrate
(55-60-04, KPL) for 1 min and then exposed to a film that was manually processed. Films
were then visualized using a Gel Doc EZ System (Bio-Rad, USA). Primary antibodies used
in this study were as follows; anti-B-TUBULIN (Sigma, T7816) (1:20,000 in 5% non-fat dry
milk), anti-COBRA1 (AbCam, ab167401) (1:1000 in 5% non-fat dry milk).

To incubate the same membrane with another primary antibody, after detection
membranes were stripped using a homemade harsh stripping buffer (0.5 M Tris-HCl, 10%
SDS and beta-mercaptoethanol). The membrane was incubated in the buffer for 15
minutes at 65°C after which it was washed thoroughly with water to remove any traces of
beta-mercaptoethanol and re-blocked with 5% nonfat dry milk in 1X PBST before
incubating it with another primary antibody.

2.9. Scratch Wound Healing Assay
Differences in cell migration were assessed using a classical scratch wound healing assay
as previously described (Qin & Cheng, 2010; Yu et al., 2014). Twenty-four hours posttransfection, cells were reseeded in 24-well plates. At 72 hr post-transfection, the cell
monolayer was carefully scraped using a 20 μl pipette tip, once horizontally and once
vertically to create a cross in the center of the well. The cells were then washed with PBS
to remove any floating cells and then incubated for another 24 hrs. The migration of the
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cells was monitored with an inverted microscope. Images were taken with phase contrast
at 10X magnification power at the start (0 hr) and at the end (24 hr) of the incubation. Three
different wound locations were chosen per well. The wound area was analyzed using the
TScratch software (Gebäck, Schulz, Koumoutsakos, & Detmar, 2009) and the percentage
wound closure was then calculated as follows:
Percentage wound closure = [(wound area24 hr/wound area0 hr)/ wound area24 hr] x 100

2.10. Data Analysis
Densitometric analysis was performed using ImageJ Software (National Institute of Health,
USA, http://www.imagej.nih.gov/ij). For both the PCR and Western Blot, quantified band
intensities were normalized to the loading control B-ACTIN or B-TUBULIN, respectively.
Relative changes in gene expression are expressed as fold change from the negative
siRNA-transfected cells (control), unless specified otherwise.

Graphical representations and statistical analyses were performed using GraphPad Prism
5.0 (GraphPad, San Diego California USA, http://www.graphpad.com/). All values
represent the mean ± standard deviation (SD) from three independent experiments, unless
specified otherwise. For pairwise comparisons, statistical significance was assessed using
an unpaired student's t-test (two-tailed). One-way ANOVA, followed by a Bonferroni posttest was used to analyze the difference between multiple experimental groups in case of a
single variable, while a two-way ANOVA was used in cases of two variables. A p-value
less than 0.05 was considered significant (*p <0.05; **p value <0.01; ***p value <0.001).

2.11. Data Mining
The Oncomine cancer microarray database (http://www.oncomine.org/, last accessed July
18, 2015) (Rhodes et al., 2004) was used to query the expression profile of COBRA1
mRNA in HCC tissues versus their normal counterparts. Statistical significance was
automatically computed by the default Oncomine algorithms using a two-tailed Student’s
t-test. HCC microarray datasets utilized in this study are summarized in Table 3.
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Table 3. Oncomine microarray datasets used in this study.
Study

Sample Type

No. of
Patients
(n)

Patients
/Sample

Year of
Study

Reference

Mas
Liver

Normal Liver
Cirrhotic
Hepatocellular Carcinoma

115

19
58
38

2009

(Mas et al.,
2009)

Roessler
Liver

Paired Non-Tumor
Hepatocellular Carcinoma

43

21
22

2010

(Roessler et
al., 2010)

Roessler
Liver 2

Paired Non-Tumor
Hepatocellular Carcinoma

445

220
225

2010

(Roessler et
al., 2010)

Wurmbach
Liver

Normal Liver
Cirrhotic
Liver Cell Dysplasia
Hepatocellular Carcinoma

75

10
13
17
35

2007

(Wurmbach
et al., 2007)
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CHAPTER 3. RESULTS

3.1. Expression of COBRA1 mRNA in human hepatocellular carcinoma tissues
relative to normal liver tissue
All publicly available HCC microarray data in the Oncomine® Cancer Microarray database
(http://www.oncomine.org/) were analyzed in order to explore the differential expression of
COBRA1 at the RNA level. A query search on the differential expression of COBRA1 in
HCC tumor tissues versus normal liver tissue yielded results from 4 different datasets, from
3 independent studies (Mas et al., 2009; Roessler et al., 2010; Wurmbach et al., 2007). In
both the Mas and Wurmbach study, samples were from patients with an HCV etiology with
no other known HCC etiologies or CLD causes (Mas et al., 2009; Wurmbach et al., 2007).
However, the vast majority of the samples in the Roessler study were from patients with a
history of HBV infection or HBV-related cirrhosis (Roessler et al., 2010).

The analysis of these datasets revealed a significant overexpression of COBRA1 mRNA
in HCC tumor tissues versus their normal tissue counterparts (p ≤ 0.05) (Figure 1).
Although 1 of the 4 datasets (Mas et al., 2009) found that COBRA1 expression did not
differ significantly between normal liver tissue and either cirrhotic or HCC tissue, the
remaining 3 datasets (Roessler et al., 2010; Wurmbach et al., 2007) demonstrated
otherwise. All 3 datasets show a significant overexpression of COBRA1 mRNA in HCC
tumor tissues versus normal or non-tumor liver tissue. Both the Roessler Liver 2 and Liver
datasets (Roessler et al., 2010) show comparable results, with a fold change of 1.614
(p=2.61E-43) and 1.635 (p=5.29E-6), respectively (Figure 1). In agreement with the
Roessler datasets, the Wurmbach et al. (2007) study shows a similar result as well with a
fold change of 1.402 (p=0.002). In the latter, no significant differences in expression were
observed between normal tissue & either cirrhotic or dysplastic tissue.

3.2. siRNA-mediated knockdown of COBRA1 in the HCC cell line, HepG2
Having noted an upregulated expression pattern for COBRA1 in HCC tumors from both
our previous lab findings (Kamel, 2012) as well as from our in silico study (Roessler et al.,
2010; Wurmbach et al., 2007), we analyzed the effect of siRNA-mediated knockdown of
COBRA1 on the HCC cell line, HepG2. To efficiently knockdown COBRA1, the different
transfection conditions (siRNA concentration, volume of the lipid-based reagent, in this
case, Lipofectamine and the duration of incubation) had to be initially optimized following
the supplier’s recommendations, in order to achieve the highest knockdown efficiency.
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Figure 1. Overexpression of COBRA1 mRNA in hepatocellular carcinoma versus
normal liver tissue The Oncomine™ cancer database of publicly available microarray data
was queried to examine the differential expression of COBRA1 in hepatocellular carcinoma
versus normal liver tissue. Three datasets from 2 independent studies (Roessler et al., 2010;
Wurmbach et al., 2007) were analyzed (A) Roessler Liver 2 dataset (B) Roessler Liver
dataset (C) Wurmbach Liver dataset. Oncomine™ results are illustrated as boxplots, with the
top and bottom of the box representing the lower quartile and upper quartile, respectively and
the bar across the box, the median. The bars represent the 10th and 90th percentile and dots
represent the minimum and maximum values (range of data within each category). For each
study, the number of patients in each category is indicated in brackets as well as the fold
change and p value as determined by the Student’s t-test. * p < 0.05; **** p < 0.0001.
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3.2.1. siRNA concentration

The concentration of siRNA is an important transfection parameter. Concentrations that
are too high can risk off-target activity, where the siRNA will not only result in the
degradation of the mRNA of interest but will degrade other mRNAs that are partially
homologous or even non-homologous (Semizarov et al., 2003). On the other hand, siRNA
concentrations that are too low will result in low knockdown efficiencies. Different
concentrations across the range recommended by the supplier were tested; 25 nM, 50 nM,
and 100 nM. Knockdown efficiency was analyzed 96 hr following transfection by a Western
blot, and as shown in Figure 2A, all tested siRNA concentrations resulted in comparable
knockdown efficiencies. Being the lowest concentration to result in an efficient protein
knockdown, the 25 nM was therefore used for all subsequent siRNA transfections. It is
important to mention that cell viability as observed by microscopy, was jeopardized in all
siRNA and mock-treated cells. However, this was not the case in untreated cells. This is
usually associated with most commonly used lipid-based transfection reagents and was
addressed by optimizing the volume of Lipofectamine.

3.2.2. Incubation duration

RNAi-mediated knockdown is known for being a transient knockdown and not a stable one.
To achieve maximal protein knockdown while allowing at the same time sufficient time for
phenotypic changes to be visible, time points for analysis should typically range from 4896 hrs. To identify the optimum time for analysis, knockdown efficiency was analyzed at
both 72 hr and 96 hr post-transfection. As shown in Figure 2B, at both time points,
knockdown efficiency was comparable showing no significant difference. Therefore, all
subsequent siRNA transfections in the HepG2 cell line were performed at 72 hrs.

3.2.3. Lipofectamine volume

The volume of Lipofectamine is also an important parameter that has to be optimized. Too
much will expose the cells to unnecessary stress, while too little will jeopardize transfection
efficiency. Here, two different strategies recommended by the supplier were analyzed.
First, the titration of the volume of Lipofectamine within the range recommended by the
supplier (4-6 μl) to determine the lowest volume of Lipofectamine required to ensure an
efficient knockdown. Second, the addition of more FBS-supplemented media 6-8 hr from
transfection while keeping the same established Lipofectamine volume (6 μl). The cells
transfected with 6 μl of Lipofectamine (with or without 8 hr media addition) showed the
highest knockdown, with an almost complete knockdown. Similarly, cells transfected with
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Figure 2. Optimization of transfection conditions of COBRA1 siRNA in HepG2. For each
transfection parameter, different conditions were compared with respect to their knockdown
efficiency, which was analyzed by Western blot analysis. Optimization of (A) siRNA
concentration. Different concentrations (25 nM, 50 nM and 100 nM) were analyzed. For all
tested concentrations, volume of Lipofectamine (6 μl) and incubation time (96 hr) were kept
constant. (B) Incubation duration. Knockdown efficiency was analyzed at both 72 hr and 96
hr post-transfection. siRNA concentration (25 nM) and volume of Lipofectamine reagent (6 μl)
were kept constant. (C) Lipofectamine volume. Lipofectamine was titrated within the range
recommended by the supplier (4, 5, 6 μl) and compared with respect to their knockdown
efficiency. In one condition, the 6 μl Lipofectamine volume was maintained and more FBSsupplemented media was added 8 hr post-transfection. The bands intensities were quantified
by ImageJ and normalized to the loading control B-TUBULIN. Relative expression is
expressed as fold change to the siNTC. siNTC - Negative siRNA, 6 μl + M - 6 μl plus media
addition 8 hr post-transfection.
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4 μl and 5 μl of Lipofectamine effectively decreased COBRA1 expression by 92% and 95%,
respectively (Figure 2C). The previously observed cytotoxicity was no longer visible in all
of the newly tested conditions. Taking into consideration knockdown efficiency as well as
cell viability, the 5 μl was chosen as the optimal volume of reagent required for transfection.
All subsequent siRNA transfections were thus performed as such.

3.3. SMARTPool siRNA effectively silences COBRA1 expression in HepG2
The COBRA1 siRNA was successful in silencing COBRA1 expression, resulting on
average in a 93% COBRA1 knockdown at the protein level, relative to the negative siRNA
(Figure 3A). To determine whether protein knockdown correlated with mRNA knockdown,
the effect of siRNA-mediated silencing of COBRA1 on the levels of COBRA1 mRNA was
analyzed by semi-quantitative PCR. As shown in Figure 3B, the pool significantly silenced
COBRA1 expression at the RNA level, which is consistent with the knockdown observed
at the protein level. No significant difference was found between the different control groups
(siNTC, mock- treated and untreated cells). It is important to mention that knockdown of
COBRA1 had no significant effect on the overall patterns of cell morphology, as observed
under the inverted microscope (40X) (Figure 4). To investigate whether COBRA1 silencing
affects the expression of the other NELF subunits as well, the mRNA expression patterns
of NELF-A, NELF-C/D, and NELF-E subunits were compared prior and after COBRA1
knockdown. Interestingly, COBRA1 knockdown did not significantly affect their expression
(p > 0.05) (Figure 5).

Figure 3. COBRA1 siRNA effectively silences COBRA1 expression at both the RNA and
protein level. (A) Knockdown efficiency of COBRA1 siRNA in silencing COBRA1 protein
levels, relative to the negative siRNA (B) RNA expression was analyzed by semi-quantitative
RT-PCR. The band intensities were quantified by ImageJ and normalized to the internal control
B-ACTIN. Relative expression is expressed as fold change to siNTC. Data represents the
mean ± SD of three independent experiments (n = 3). Statistically significant at *** p < 0.001.
siCOBRA1 - COBRA1 siRNA, siNTC - Negative siRNA.
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Figure 4. No significant morphology changes associated with COBRA1 knockdown observed in HepG2 cells (40X). Photos were taken at
40X magnification power 72 hr post-transfection for cells transfected with either COBRA1 siRNA or Negative siRNA. Cells that were either left
untreated or mock-treated with Lipofectamine only were used as controls.

Figure 5. COBRA1 knockdown does not affect the expression of the remaining NELF
subunits. Semi-quantitative RT-PCR analysis of NELF-A, NELF-C/D and NELF-E transcripts
prior and following COBRA1 knockdown. The band intensities were quantified by ImageJ and
normalized to the internal control B-ACTIN. Relative expression is expressed as fold change
to siNTC. Data represents the mean ± SD of three independent experiments (n = 3). No
statistically significant differences were observed (p > 0.05) (one-way ANOVA, Bonferonni’s
post-test). siCOBRA1 - COBRA1 siRNA, siNTC - Negative siRNA.

3.4. Silencing of COBRA1 suppresses cell proliferation of HepG2.

To examine the effect of COBRA1 knockdown on cellular proliferation, HepG2 cells, were
transfected with either 25 nM COBRA1 siRNA or Negative siRNA and harvested at different
time points. Cell counting was performed to construct a growth curve and assess the rate
of cell proliferation. Significant suppression was observed in the growth of cells transfected
with COBRA1 siRNA at day 3 and 4 post-transfection, when compared to control cells
(Figure 6).

In order to further investigate the effect of COBRA1 knockdown on cell proliferation, the
expression of an important marker of cellular proliferation, Ki-67, was examined. Ki-67 is a
nuclear protein that is present in all active phases of the cell cycle (G1, S, G2, and mitosis),
with the exception of the resting (G0) phase (Scholzen & Gerdes, 2000). Even though little
is known about the function of Ki-67, its presence is believed to be an absolute requirement
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for cell cycle progression and the maintenance of cell proliferation (Schlüter et al., 1993).
Recently, it was shown to play an important role in the stabilization and maintenance of
mitotic spindles (Vanneste, Takagi, Imamoto, & Vernos, 2009). Consistent with the
previous cell count data, semi-quantitative PCR revealed a significant reduction of ~20%
in the expression of Ki-67 mRNA upon COBRA1 knockdown, when compared to control
cells (p<0.01; Figure 7). No significant difference in the expression of Ki-67 was found
between the different control groups.
3.5. Silencing of COBRA1 inhibits cell migration of HepG2.

The effect of COBRA1 knockdown on the migratory potential of HepG2 cells was analyzed
using a classical scratch wound healing assay (Qin & Cheng, 2010; Yu et al., 2014). After
24 hr from inflicting the wound in the cell monolayer, the wound area in the transfected
cells was compared to the initial wound area and used to calculate the percentage wound
closure. Visual assessment of each well revealed a noticeable difference in the area of the
wounds; the wound area in COBRA1 knockdown cells was wider than that of the negative
control cells (Figure 8A). Wound areas were automatically analyzed by the TScratch
software and revealed a ~60% decrease in the migration rate following COBRA1
knockdown (p<0.001; Figure 8B). While the control cells showed a 31.86% wound closure
after 24 hrs, COBRA1 knockdown cells showed a delayed wound closure rate at 13.12%.
3.6. Silencing of COBRA1 significantly suppresses survivin gene expression

Deregulation of cell proliferation and migration in cancer is usually associated with the
deregulation of many key signaling pathways (Hanahan & Weinberg, 2011; Malumbres &
Carnero, 2003). To explore the underlying mechanisms by which COBRA1 regulates the
proliferation and migration of HepG2 cells, semi-quantitative PCR was utilized to examine
the expression of genes commonly reported misregulated in cancer and play key roles in
the proliferation as well as survival of cancer such as survivin. Of the 3 transcript variants
analyzed, the wild-type survivin transcript represents the dominant form of survivin in
HepG2. As shown in Figure 9A, knockdown of COBRA1 significantly suppresses the
expression of the 3 different variants of survivin compared with cells transfected with
control siRNA. While survivin-2B and survivin-deltaex3 were downregulated by 21.5% and
16.4%, respectively, the wild type (WT) survivin was the one most affected, with 40%
downregulation in the knockdown cells when compared to the control siRNA (Figure 9B).
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Figure 6. Knockdown of COBRA1 inhibits the cell proliferation of HepG2 cells. (A) The
growth of cells transfected with either COBRA1 siRNA or Negative siRNA were monitored for
4 days post-transfection in order to analyze the growth rate. Cells were harvested at the
indicated time points following transfection and counted using a hemocytometer. Data
represents the mean ± SD of at least two independent experiments (n = 2). Statistically
significant at ** p<0.01, * p < 0.05 (two-way ANOVA, Bonferonni’s post-test)

Figure 7. Effect of COBRA1 knockdown on the expression of the cellular proliferation
marker, Ki-67. Effect of COBRA1 knockdown was analyzed by semi-quantitative RT-PCR.
The bands intensities were quantified by ImageJ and normalized to the internal control BACTIN. Relative expression is expressed as fold change to the siNTC. A significant reduction
was observed in the expression of Ki-67 following COBRA1 knockdown, relative to siNTC.
Data represents the mean ± SD of 2 independent experiments (n = 3). Statistically significant
at ** p < 0.01, * p< 0.05 (one-way ANOVA, Bonferonni’s post-test). siCOBRA1 - COBRA1
siRNA, siNTC - Negative siRNA.
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Figure 8. Silencing of COBRA1 impairs HepG2 cell migration. (A) Wound healing assay
was utilized to analyze the migration of HepG2 cells after knockdown of COBRA1. Seventytwo hrs following transfection, the cell monolayer was scratched by a sterile pipette tip and
migration monitored for the following 24 hrs. (B) Quantitative analysis of wound closure in
COBRA1-knockdown cells versus negative siRNA-transfected cells. Automated analysis of
the wound area was performed using TScratch software (Gebäck et al., 2009). Wound areas
were then used to calculate the percentage wound closure. Data represents the mean ± SD
from three independent experiments (n = 3). Statistically significant at *** p < 0.001 (Student
t-test, two-tailed). siCOBRA1- COBRA1 siRNA, siNTC - Negative siRNA.
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Figure 9. Silencing of COBRA1 suppresses Survivin expression. (A) At 72 hr posttransfection of COBRA1 or Negative siRNA in HepG2 cells, the expression of Survivin was
analyzed by semi-quantitative RT-PCR. B-ACTIN was used as a loading control. Primers
used detect 3 different isoforms of Survivin; Wild-type Survivin, Survivin-2B and SurvivinDeltaEx3. (B) The bands intensities were quantified by ImageJ and normalized to B-ACTIN.
Relative expression is expressed as fold change to the siNTC. A significant reduction was
observed in the expression of all 3 isoforms of Survivin following COBRA1 knockdown,
relative to siNTC. Data represents the mean ± SD of 3 independent experiments (n = 3).
Statistically significant at ** p < 0.01, * p< 0.05 (one-way ANOVA, Bonferonni’s post-test).
siCOBRA1- COBRA1 siRNA, siNTC - Negative siRNA.
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CHAPTER 4. DISCUSSION

Despite the different treatment regimens available, prognosis of HCC remains very poor
with an overall 5-year survival rate of less than 5% (X. Huang et al., 2013), making it the
second most common cause of cancer-related mortality worldwide (Ferlay et al., 2013).
The lethal nature of HCC stems from the aggressive course of the disease combined with
the high risk of tumor recurrence (Capece et al., 2013). In addition, due to the lack of
biomarkers that can detect the disease in its early stages, the majority of HCCs are
diagnosed at advanced stages when curative surgical treatment options are no longer
available. This makes their treatment very difficult (Farazi & DePinho, 2006).

It is believed that proper molecular markers will not only aid in the early diagnosis of HCC,
but also in the prognosis and therapy monitoring of the disease. Therefore, research is
currently directed towards identifying molecular markers that are sensitive and specific
enough to allow for efficient patient management. In addition, due to the heterogeneity and
underlying complexity of HCC, the molecular mechanisms lying behind the development
and progression of HCC remain largely unknown. A comprehensive understanding of the
multiple layers of genetic and epigenetic changes associated with this disease will provide
a platform for the discovery of novel treatment strategies (Cornellà et al., 2011).

In this study, our interest was in one of the genes recently implicated as a potential player
in the development and progression of several cancers, known as COBRA1 (McChesney
et al., 2006; Sun et al., 2008). COBRA1 is part of the transcriptional regulatory machinery
of the cell, by which the cell is able to regulate a substantial number of genes (Aiyar, Blair,
et al., 2007; Aiyar, Cho, et al., 2007; Aiyar et al., 2004; Sun & Li, 2010). Even though it has
been extensively studied over the years, the majority of these studies have mostly reported
roles for COBRA1, either as a functional component (Narita et al., 2003) or as a cofactor
for site-specific transcription factors (Aiyar et al., 2004; Sun et al., 2007; Zhong et al., 2004).
In the field of cancer, the role of COBRA1 is not yet fully understood and much of the data
that currently exists regarding its role is conflicting. Nonetheless, data that exists does
demonstrate an important role for COBRA1 in cancer and the fact that much of it is
conflicting highlights the underlying complexity of COBRA1’s role. Here, we provide several
lines of evidence for the first time to support a critical role for COBRA1 in supporting HCC.
4.1. Overexpression of COBRA1 in HCC tumor tissues versus normal liver tissue
To date, little is known about COBRA1 in HCC. Previous research in Amleh’s Lab (Kamel,
2012) provides preliminary data supporting an upregulated expression pattern for COBRA1
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mRNA (68%) and protein (50%) in HCC tumor tissues, when compared to peri-tumor
tissues collected from the same patient. However, the small sample size was a major
limitation of the study. In the current study, we extended on the lab’s previous data findings
and utilized microarray data publicly available online to further explore this variation in
expression on a larger scale. Analysis of HCC microarray data available in the Oncomine
database revealed 3 datasets that collectively demonstrated a significant overexpression
of COBRA1 mRNA (1.4-1.6 folds) in HCC tumor tissues versus normal liver tissues.
Chronic HBV and HCV infection have together the majority of the share in the incidence of
HCC. Similar to previous research in Amleh’s lab, samples in the Wurmbach study were
from patients with an HCV etiology. In contrast, the large majority of the samples in the
Roessler study were from patients with a history of HBV infection or HBV-related cirrhosis.
This strongly suggests that the overexpression of COBRA1 is a feature associated with
both etiologies of HCC. It is important to mention that even though 3 datasets were in
agreement with regards to the differential expression of COBRA1 between HCC tissue and
either normal liver or paired non-tumor tissue, one dataset (Mas Liver dataset) did not show
any significant difference. However, this might be attributed to experimental factors related
to variabilities in RNA handling, used probe sequences or differences in the computational
methods used. Therefore, further meta-analysis of data from these datasets is necessary
to gain a more reliable insight.
Furthermore, the Mas Liver dataset does not show any difference in the expression of
COBRA1 between normal tissue and cirrhotic tissue. In agreement, the Wurmbach dataset
also shows no difference between normal liver tissue & either cirrhotic or dysplastic tissue.
This data suggests the potential of COBRA1 as a biomarker in differentiating HCC from
other chronic liver disorders. However, this still requires further study on a wider range of
samples. Taken together, data presented here demonstrates the frequent overexpression
of COBRA1 in HCC tumors versus their normal counterparts and suggests a potential
oncogenic role for COBRA1.

4.2. Efficiency of SMARTPool siRNA in the Silencing of COBRA1

To clarify a role for the frequent overexpression of COBRA1 in HCC, RNA interference
(RNAi) was used to silence COBRA1 expression. RNAi is the cellular mechanism by which
double stranded RNAs trigger silencing of gene expression, by targeting complementary
mRNA sequences for degradation (Echeverri & Perrimon, 2006). With a higher expression
of COBRA1 mRNA and protein relative to the normal human hepatocyte cell line MIHA,
the HepG2 cell line (as observed by Amleh Lab) was chosen as our cell model.
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Despite its power, off-target activity is inherent to the siRNA technology and complicates
the interpretation of all knockdown experiments. Attempts so far have only been able to
reduce but not eliminate off-target activity (Echeverri et al., 2006; Jackson & Linsley, 2010).
Due to the concerns over off-target activity commonly associated with siRNAs combined
with the large variabilities that exist in the knockdown efficacies of individual siRNAs, it has
become standard practice in siRNA experiments to analyze different siRNAs per target (at
least 2-3). There are 2 common approaches by which these siRNAs can be delivered;
either individually or as pools. Conflicting data exists regarding the pros & cons associated
with using either. Nonetheless, both remain standard knockdown strategies (Echeverri et
al., 2006; Parsons, Schindler, Evans, & Foley, 2009).

Here, a siRNA pool was utilized to establish a transient COBRA1 knockdown in the HepG2
cell line. The strong, near complete knockdown observed indicated that the siRNAs were
successful in silencing COBRA1 expression at the protein level. This was important for our
study as it was previously reported that a silencing threshold must sometimes be reached
before a detectable loss-of-function (LOF) phenotype can be observed. In fact, the authors
reported that sometimes a complete protein knockdown is essential in order to make an
accurate assessment of gene function (F. Huang, Khvorova, Marshall, & Sorkin, 2004). In
support, a recent study reported experiments performed with pooled siRNAs to be more
likely associated with LOF phenotypes than single siRNAs (Parsons et al., 2009).
In addition, Dharmacon RNA Technologies (http://www.dharmacon.com/) have shown that
their pooling strategy of 4 different siRNAs superior to individual siRNAs in diluting offtarget effects. With each siRNA having a distinct off-target signature of its own, the overall
off-target signature of the entire pool is less than any of the individual siRNAs. Furthermore,
pooling siRNAs is known to reduce the contribution of each of the single siRNAs to the final
pool and thus perceived to reduce off-target activity. In this respect, Semizarov et al. (2003)
reported siRNA concentrations ≤ 20 nM sufficient to eliminate off target activity. In our
study, 25 nM of the pool was used. Thus, ~6.25 nM from each of the 4 single siRNAs.
Nonetheless, it is still important to mention that off-target activity is impossible to rule out
and much of the data that exists regarding how it should be minimized is conflicting.
Therefore, to ensure a more rigorous study, further analysis of the single siRNAs that
constitute the pool is necessary.
4.3. Knockdown of COBRA1 Inhibits Cellular Proliferation of HepG2

Deregulation of cellular proliferation is one of the major hallmarks of cancer (Hanahan &
Weinberg, 2011; Malumbres & Carnero, 2003). Here, our data indicates that COBRA1 is
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essential for maintaining the cellular proliferation rates of the HepG2 cell line. This positive
effect that COBRA1 has in mediating the growth of HCC goes in line with its previously
reported role in maintaining the transcription of a large number of genes involved in cell
cycle control, cell proliferation, cell death and DNA repair (Aiyar, Blair, et al., 2007; Aiyar,
Cho, et al., 2007). In fact, this is not the first time COBRA1 has been implicated in the
proliferation of cancer. Aiyar et al. (2004) reported a significant reduction in the rate of
proliferation of T47D cells upon the ectopic expression of COBRA1. Similarly, knockdown
of COBRA1 resulted in an increase in the estrogen-dependent growth of the cells, thereby
establishing an inhibitory role for COBRA1 in breast cancer tumorigenesis. However, in
contrast to breast cancer, COBRA1 knockdown significantly inhibited HepG2 proliferation
as shown by both the reduced count and decrease in the expression of Ki-67. Taken
together, data presented here supports a positive role for COBRA1 in the growth of HCC.

These findings go in line with other studies that also suggest a positive role for COBRA1
in the growth of both ovarian and lung cancer. In both cancers, COBRA1 was shown a
novel target of the widely established oncogenic Ras/MAPK pathway (Pohl et al., 2005;
Sudhir et al., 2011). Chemical inactivation of the pathway resulted in a profound decrease
in the proliferation of different ovarian cancer cell lines accompanied by a substantial
downregulation (>3-fold) in the expression of COBRA1 (Pohl et al., 2005). It is important
to mention that the contribution of COBRA1’s downregulation towards the observed
phenotype is still not known. Nonetheless, the fact that COBRA1 was identified as a target
of the pathway and the impact of this pathway in supporting carcinogenesis, strongly
suggest a positive role for COBRA1 in mediating the effects of this pathway.

4.4. Knockdown of COBRA1 Inhibits Migratory Potential of HepG2

Local invasion and distant metastasis is another key cancer hallmark and an indicator of
poor prognosis (Hanahan & Weinberg, 2011). In line with COBRA1’s established role in
breast cancer as a tumor suppressor, lack of COBRA1 in cancerous tissues is associated
with distant metastasis and recurrence in patients and thus considered as an indicator of
poor prognosis (Sun et al., 2008). In agreement, the expression pattern of many genes
reported earlier to be regulated by COBRA1 have been associated with advanced and/or
metastatic breast cancer (Aiyar, Blair, et al., 2007; Aiyar, Cho, et al., 2007; Aiyar et al.,
2004). In contract to breast cancer, where COBRA1’s expression is inversely correlated
with metastasis, our data findings suggests a positive role for COBRA1 in metastasis. The
molecular basis behind the tissue-specific nature of COBRA1’s functions remain unknown
and warrants further study. It is also important to mention that this study has to be further
extrapolated to other cell lines to gain a comprehensive understanding of COBRA1 in HCC.
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4.5. Interdependent Nature of NELF Subunits

COBRA1 is a functional component of the NELF complex. It has been reported that upon
knockdown of any NELF subunit, co-depletion of the remaining subunits occur almost
simultaneously (Narita et al., 2007; Sun & Li, 2010; Sun et al., 2008). Even though our
results show otherwise, findings from these studies have shown that the changes observed
in the expression levels of the NELF subunits occurred exclusively at a post-transcriptional
level (Narita et al., 2007; Sun & Li, 2010; Sun et al., 2008). Therefore, further examination
is required before a conclusion can be drawn here.

Similar to COBRA1, the rest of the NELF subunits (NELF-A, NELF-C/D and NELF-E) have
also been implicated in different cancers (Mehra et al., 2011; Oka, 2012; Zou et al., 2010).
Given the previously established interdependent nature of the NELF subunits (Narita et al.,
2007; Sun & Li, 2010; Sun et al., 2008), a disease-based deregulation in the expression
pattern of one subunit is expected to equally reflect in the remaining subunits. It is therefore
tempting to speculate overlapping roles for the different NELF subunits in the same cancer.
Limited with the small number of studies, this pattern has been observed so far in breast
cancer. Both NELF-B (COBRA1) and NELF-C/D were reported independently to have
negative roles in the growth and progression of breast cancer. In addition, the expression
of either negatively correlated with the aggressiveness of breast cancer (Sun et al., 2008;
Zou et al., 2010). Here, we believe our results follow the same pattern and goes in line with
previous data published regarding the role of other NELF subunits in HCC. NELF-E (also
known as RDBP) was shown to have a higher expression pattern in HCC tumors versus
their paired non-HCC tissues. In line with its preferential overexpression in tissues with
portal vein invasion, NELF-E expression was also reported an independent risk factor for
intrahepatic recurrence. Furthermore, knockdown of NELF-E resulted in a decrease in cell
proliferation rate of the hepatoma cell line, HLE, with no significant changes observed in
the cell cycle distribution (Oka, 2012). This was also earlier established by Midorikawa et
al. (2002) who reported the dedifferentiation process of HCC, one of the events that define
the multi-step progression of hepatocarcinogenesis, associated with the overexpression of
RDBP, among others.

4.6. Silencing of COBRA1 Suppresses Survivin Expression
Survivin represents one of the genes that is commonly upregulated in almost all human
malignancies including HCC and known to play key roles in cellular proliferation and
survival (Fukuda & Pelus, 2006). It is a member of the inhibitor of apoptosis (IAP) family of
proteins that play key roles in inhibiting different pathways of programmed cell death
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(Elmore, 2007). While in normal tissue survivin has minimal expression levels, in cancer
its expression is upregulated and correlates with a more aggressive disease and a poor
prognosis (Jaiswal, Goel, & Mittal, 2015). Survivin expression is cell-cycle dependent,
being low in the G1 phase, high in the S phase (6 times higher) and at its peak in the G2/M
phase (40 times higher) (Boidot, Végran, & Lizard-Nacol, 2014). In line with its cell cycledependent expression, survivin functions mainly as both a regulator of cell division and an
inhibitor of apoptosis (Mita, Mita, Nawrocki, & Giles, 2008).
Besides the 4-exon WT survivin transcript, at least 6 alternatively spliced variants have
been identified to date: WT survivin, survivin-2b, survivin-ΔEx3, survivin-3b, survivin-2a,
survivin-2b+32 and survivin-image (Pavlidou, Kroupis, & Dimas, 2014). Of those, only 3
are well established and have been extensively studied. These are the WT survivin,
survivin-2b and survivin-ΔΕx3. In one study, the 3 variants were shown to represent nearly
98% of the mRNA expression from the survivin gene (Mull, Klar, & Navara, 2014). While
survivin-2b arises from the inclusion of a cryptic exon that lies within intron 2, survivin-ΔΕx3
arises from the removal of exon 3 and a frameshift that results in the inclusion of part of
the 3’-untranslated region (UTR) (Li, 2005; C Mahotka, Wenzel, Springer, Gabbert, &
Gerharz, 1999) (Figure 10).

Figure 10. Alternatively Spliced Survivin Transcripts. The survivin pre-mRNA includes four
exons (exon 1-4) and two cryptic exons (exon 2b, 3b). The survivin pre-mRNA generates at
least seven alternatively spliced variants identified to date. The forward and reverse primers
used in this study pick up only three of these survivin transcripts: WT survivin, survivin-2b and
survivin-ΔEx3. WT survivin is derived from exons 1-4. Survivin-2b arises from the inclusion of
a cryptic exon referred to as exon 2b, located within intron 2. Survivin-ΔΕx3 arises from the
removal of exon 3 and inclusion of part of the 3’-UTR. Black arrows indicate the positions of
PCR primers (Exon 1 and exon 4). WT: wild type, UTR: untranslated region (Mokuda et al.,
2015; Turkkila et al., 2015)
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Even though, these 3 variants have been extensively studied, little is known about their
functions. In contrast to WT survivin, survivin-2b and survivin-ΔEx3 do not seem to have a
role in the regulation of cell division (Noton et al., 2006). Instead, they have only been
shown until now to play a role in the regulation of apoptosis; while survivin-ΔEx3, similar
to WT survivin has an anti-apoptotic function, survivin-2b is believed to have a proapoptotic function (Pavlidou et al., 2014). Even though this is the case, reported data for
survivin-2b sometimes suggest otherwise (Y. Huang et al., 2011; Nakano et al., 2008;
Vivas-Mejia et al., 2011).

Our results show that of the 3 transcripts examined, WT survivin represents the dominant
splice variant expressed in HCC which goes in line with previous literature (Kannangai,
Wang, Liu, Sahin, & Torbenson, 2005). In fact, it is worth to mention that the predominant
expression of WT survivin has been reported in many other cancers as well (Fangusaro et
al., 2005; Krieg et al., 2002; Csaba Mahotka et al., 2002; Ryan et al., 2005; Taubert et al.,
2005). In HCC, Takashima et al. (2005) reported that that high levels of WT survivin mRNA
correlated with a more malignant cancer. In addition, it was shown that while the mRNA
expression levels of WT survivin and survivin-ΔEx3 correlated with high proliferative
activity, that of survivin-2b did not (Takashima et al., 2005). Even though not enough data
is available to draw a conclusion for the role of survivin-2b in HCC, the overexpression of
survivin transcripts observed in HCC compared to normal tissue is believed to be
associated with hepatocarcinogenesis (Kannangai et al., 2005; Takashima et al., 2005).
Therefore, taken together, the suppression of survivin expression upon COBRA1
knockdown suggests that survivin might be one of the mechanisms by which COBRA1
mediates its involvement in HCC growth and migration. It is also worth to mention that this
finding is in line with a previously published microarray study in breast cancer that also
demonstrated survivin to be downregulated upon COBRA1 knockdown (Aiyar, Cho, et al.,
2007).
In summary, COBRA1’s role in cancer seems to be highly cancer type-dependent. While
previously reported a tumor suppressor in breast cancer with an expression pattern directly
correlated with prognosis, data in UGCs seems to support its role as an oncogene
(McChesney et al., 2006; Sun et al., 2008). Here, in HCC, our data findings collectively
highlight an oncogenic role for COBRA1 in HCC, similar to that in UGC.
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CONCLUSION
To the best of our knowledge, our study provides several lines of evidence for the first time
to support a positive role for COBRA1 in the growth and migration of HCC.
First, we show through in silico analysis of publicly available gene expression data on a
large number of tissue samples, the frequent overexpression of COBRA1 in HCC tumors
versus their normal counterparts. In addition, we highlight the potential of COBRA1 as a
selective HCC biomarker, given no differences in COBRA1 gene expression were found
between normal tissue and tissue from other non-HCC chronic liver diseases. Second, we
show that COBRA1 expression is important for the proliferation and migration of HCC cells.
Finally, the deregulation of cell proliferation and migration observed in cancer is usually
associated with the deregulation of multiple mechanisms that normally exist to suppress
tumor formation and metastasis. Here, data findings from our study also show that one of
the possible mechanisms by which COBRA1 mediates its positive role on the growth and
migration of HCC might be through the upregulation of survivin expression.
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FUTURE RECOMMENDATIONS

Microarray data remains to date a rich, untapped source of knowledge that remains largely
underutilized. Further analysis of publicly available HCC gene expression datasets should
be done, to study the correlation between COBRA1 expression and clinicopathological
parameters. This will help clarify the potential of COBRA1 mRNA as a prognostic factor, in
predicting the aggressiveness of HCC. Analysis should also be extrapolated to the protein
level via immunohistochemistry of tissue arrays.

As earlier discussed, off-target effects are inherent to the siRNA technology and attempts
have so far have only been able to reduce but not eliminate off-target activity (Echeverri et
al., 2006). Even though the utilized pooling strategy has been shown by Dharmacon RNA
Technologies (http://www.dharmacon.com/) to dilute off-target effects observed with single
siRNAs, the superiority of pooled siRNAs to individual siRNAs in this respect remains
controversial among researchers (Echeverri & Perrimon, 2006; Smith, 2006). Confirmation
with redundant silencing reagents remains the gold standard for demonstrating siRNA
specificity (Echeverri et al., 2006). Therefore, our data should be further confirmed with at
least 2-3 individual siRNAs. In addition, analysis of the effect of COBRA1 overexpression
in HepG2 will further validate the specificity of our data findings.

Extrapolation of the methodology to include more HCC cell lines, representing different
stages of HCC, will ensure a more reliable assessment of COBRA1’s function. In addition,
further analyses of COBRA1-knockdown cells should be done for a more comprehensive
understanding. For example, cell cycle analysis can be performed to further investigate the
molecular mechanisms underlying the decrease in proliferation by analyzing both the cell
cycle distribution (G1, G2 and S phases) and the apoptotic cell fraction upon knockdown.

The frequent overexpression of COBRA1 mRNA in HCC tumors raises the question of as
to how this upregulation is achieved and the molecular mechanisms behind it. Further
studies should investigate whether the oncogenic Ras/MAPK pathway, as an upstream
regulator of COBRA1, plays a role in mediating COBRA1’s positive role in HCC
proliferation & migration. In addition, given COBRA1’s role in suppressing AR-signaling
pathway and the impact of this pathway in mediating carcinogenesis of HCC, it would be
interesting also to find out the functional link between both in HCC.
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